Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SP263 and 22-C3 assays failed to reproduce SP142 clinical validity in the context of the IMpassion-130 trial.
“SP263 (Ventana) and 22-C3 (Dako), both of which are widely used in pathology laboratories for other tumour types, have been evaluated for their clinical validity in the context of the IMpassion-130 trial but failed to reproduce SP142 clinical validity.90”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369 · see citing works
“SP263 (Ventana) and 22-C3 (Dako), both of which are widely used in pathology laboratories for other tumour types, have been evaluated for their clinical validity in the context of the IMpassion-130 trial but failed to reproduce SP142 clinical validity.(90) Thus, PD-L1 status by SP142 is the companion test for the use…”
MethodSelf-citationAtezolizumab for the treatment of breast cancer
Reddy, S. M., Carroll, E., & Nanda, R. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1732211 · Cited by 94 · see citing works
Refining patient selection for breast cancer immunotherapy: beyond PD-L1
Kossai, M., Radosevic-Robin, N., & Penault-Llorca, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100257 · Cited by 36 · see citing works
- Authors
- Rugo, H. S., Loi, S., Adams, S., Schmid, P., Schneeweiss, A., Barrios, C. H., Iwata, H., Dieras, V. C., Winer, E. P., Kockx, M., Peeters, D., Chui, S. Y., Lin, J. C., Nguyen Duc, A., Viale, G., Molinero, L., & Emens, L. A.
- Affiliations
- University of California, San Francisco (US)
- Peter MacCallum Cancer Centre (AU)
- NYU Langone Health (US)
- Queen Mary University of London (GB)
- German Cancer Research Center (DE)
- Pontifícia Universidade Católica do Rio Grande do Sul (BR)
- Aichi Cancer Center (JP)
- Centre Eugène Marquis (FR)
- Dana-Farber Cancer Institute (US)
- HistoGeneX (Belgium) (BE)
- Genentech (US)
- University of Milan (IT)
- UPMC Hillman Cancer Center (US)
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 30
- Pages
- v858-v859
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2997305322
- Cited by
- 116
- References
- 0
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 11 · 2022: 20 · 2021: 44 · 2020: 29 · 2019: 3
- FWCI
- 10.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- U.S. Department of Defense
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Teva Pharmaceutical Industries
- Celgene
- Celldex Therapeutics
- Les Laboratories Pierre Fabre
- BeiGene
- Incyte
- Puma Biotechnology
- Eisai
- Astellas Pharma
- Servier
- PharmaMar
- Genentech
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
- Keywords
- PD-L1 immunohistochemistry, triple-negative breast cancer, metastatic breast cancer, atezolizumab, nab-paclitaxel, SP142, SP263, 22C3, assay concordance, predictive biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
